Close

CTSZ

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CTSZ (Cathepsin Z) is a Protein Coding gene. Diseases associated with CTSZ include Dacryoadenitis. Among its related pathways are Peptide hormone metabolism and Clathrin derived vesicle budding. Gene Ontology (GO) annotations related to this gene include cysteine-type peptidase activity. An important paralog of this gene is CTSC.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-CQ0689 Anti-CTSZ (CBXC-3015) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXC-3015 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ0690 Anti-CTSZ (CBXC-0983) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXC-0983 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ4113 Anti-CTSZ (CBXC-3015) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXC-3015 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ4114 Anti-CTSZ (CBXC-0983) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXC-0983 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY3036 Anti-CTSZ (CBFYC-2464) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYC-2464 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY3037 Anti-CTSZ (CBFYC-2465) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYC-2465 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY3038 Anti-CTSZ (CBFYC-2466) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBFYC-2466 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY6289 Anti-CTSZ (CBFYC-2464) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYC-2464 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY6290 Anti-CTSZ (CBFYC-2465) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYC-2465 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WFY6291 Anti-CTSZ (CBFYC-2466) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBFYC-2466 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ0707 Anti-CTSZ (AT6G11) h(41BB-CD3ζ) CAR, pCDCAR1 Human AT6G11 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ0708 Anti-CTSZ (CBWJC-3442) h(41BB-CD3ζ) CAR, pCDCAR1 CBWJC-3442 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ0709 Anti-CTSZ (CBWJC-3443) h(41BB-CD3ζ) CAR, pCDCAR1 CBWJC-3443 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ2999 Anti-CTSZ (AT6G11) h(CD28-CD3ζ) CAR, pCDCAR1 Human AT6G11 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3000 Anti-CTSZ (CBWJC-3442) h(CD28-CD3ζ) CAR, pCDCAR1 CBWJC-3442 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-WJ3001 Anti-CTSZ (CBWJC-3443) h(CD28-CD3ζ) CAR, pCDCAR1 CBWJC-3443 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.